| Name | CCR2 antagonist 1 |
|---|---|
| Synonyms |
CCR2 antagonist 1,CCR-2 antagonist 1
Methanone, [(1S,3R)-3-[[(1R)-5-bromo-2,3-dihydro-1H-inden-1-yl]amino]-1-(1-methylethyl)cyclopentyl][3,4-dihydro-7-(trifluoromethyl)-2(1H)-isoquinolinyl] |
| Description | CCR2 antagonist 1 is a high-affinity and long-residence-time CCR2 antagonist, with a Ki of 2.4 nM. |
|---|---|
| Related Catalog | |
| Target |
CCR2:2.4 nM (Ki) |
| In Vitro | The combination of SAR and SKR in the hit-to-lead process results in the discovery of a new higheaffinity and longeresidenceetime CCR2 antagonist (CCR2 antagonist 1 (compound 15a), Ki=2.4 nM; RT=714 min)[1]. |
| References |
| Molecular Formula | C28H32BrF3N2O |
|---|---|
| Molecular Weight | 549.47 |